Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
01.12.21
/
0%
€4.85
Target price
01.12.22
-
Performance (%)
-53.67%
End price
02.12.22
€2.25
Summary
This prediction ended on 02.12.22 with a price of €2.25. The BUY prediction by Maxi_Scalibusa for Arbutus Biopharma Corp. performed very badly with a performance of -53.67%. This prediction was marked as speculative and is excluded from Maxi_Scalibusa's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arbutus Biopharma Corp. | 13.277% | 13.277% | 44.557% | 49.907% |
| iShares Core DAX® | 3,59 % | 3,93 % | 15,38 % | 53,20 % |
| iShares Nasdaq 100 | 5,81 % | 5,52 % | 41,46 % | 91,09 % |
| iShares Nikkei 225® | 4,08 % | 8,46 % | 48,95 % | 63,93 % |
| iShares S&P 500 | 4,14 % | 4,04 % | 31,59 % | 64,84 % |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
